A monthly digest of research on company ingredients published in peer-reviewed journals
Study claim: Lacidofil brand probiotics blend halves the risk of H pylori colonisation of the digestive tract in rats.
Published: Johnson-Henry KC, et al. Probiotics reduce bacterial colonization and gastric inflammation in H pylori-infected mice. Dig Dis Sci 2004 Aug; 49(7-8):1095-102.
Abstract: The goal was to determine if pretreatment with a commercial mix of live probiotics (L rhamnosus, strain R0011, and L acidophilus, strain R0052) would suppress colonisation of H pylori, strain SS1.
Thirty female mice were divided into four groups: group A was fed sterile water, group B received probiotics in sterile water, group C was challenged orogastrically with H pylori, and group D was pretreated with probiotics in drinking water prior to and following challenge with H pylori. Tissue samples from the stomach were analysed histologically to determine the degree of H pylori colonisation, mucosal inflammation and epithelial cell apoptosis.
Probiotics in drinking water did not affect the overall wellbeing of mice. Lactobacillus species were excreted in stools over the duration of treatment. Pretreatment with probiotics reduced the number of mice with H pylori growth from stomach homgenates (100 to 50 per cent). The percentage of mice with moderate-severe H pylori-induced inflammation in the gastric antrum was reduced with probiotic pretreatment (71 to 29 per cent). However, pretreatment with probiotics did not prevent H pylori-induced apoptosis in the gastric mucosa.
Potential applications: Lacidofil could become a safe and effective solution to prevent infection and improve eradication of H pylori, which is implicated in most peptic ulcers and some gastric cancers.
More info: +33 562 745 555
Study claim: Use of a cetylated fatty acid topical cream can improve knee range of motion; ability to ascend/ descend stairs; ability to rise from sitting, walk and sit down; and unilateral balance.
Published: Kraemer WJ, et al. Effect of a cetylated fatty acid topical cream on functional mobility and quality of life of patients with osteoarthritis. J Rheumatol 2004 Apr; 31(4):767-74.Abstract: Forty patients, age 63 +/- 10 years, diagnosed with knee osteoarthritis were assigned to one of two topical treatment groups: cetylated fatty acid (CFA) or placebo. Patients were tested at baseline (T1), 30 minutes after initial treatment (T2), and after 30-day treatment of cream application twice per day (T3). Assessments included knee range of motion, timed ?up-and-go? from a chair and stair climbing, medial step-down test, and unilateral anterior reach.
For stair climbing and the up-and-go test, significant decreases in time were observed at T2 and T3. Supine range of motion increased at T2 and T3 in CFA group, with no difference in placebo group. For medial step-down, significant improvement was observed at T2 and T3. For unilateral anterior reach, significant improvement was observed for both legs in CFA group and in only the left leg in the placebo group. Improvements observed in CFA group were significantly greater than placebo group for both legs.
Potential applications: Celadrin, by Imagenetix, is available orally and topically.
More info: +1 905-512-5058
To submit newly published research on your company?s ingredients, please email email@example.com for details.